Search
Results: 13
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes
Robert W. Koivula, Ian M. Forgie, Azra Kurbasic, Ana Viñuela, Alison Heggie, Giuseppe N. Giordano, Tue H. Hansen, Michelle Hudson, Anitra D. M. Koopman, Femke Rutters, Maritta Siloaho, Kristine H. Allin, Søren Brage, Caroline A. Brorsson, Adem Y. Dawed, Federico De Masi, Christopher J. Groves, Tarja Kokkola, Anubha Mahajan, Mandy H. Perry, Simone P. Rauh, Martin Ridderstråle, Harriet J. A. Teare, E. Louise Thomas, Andrea Tura, Henrik Vestergaard, Tom White, Jerzy Adamski, Jimmy D. Bell, Joline W. Beulens, Søren Brunak, Emmanouil T. Dermitzakis, Philippe Froguel, Gary Frost, Ramneek Gupta, Torben Hansen, Andrew Hattersley, Bernd Jablonka, Jane Kaye, Markku Laakso, Timothy J. McDonald, Oluf Pedersen, Jochen M. Schwenk, Imre Pavo, Andrea Mari, Mark I. McCarthy, Hartmut Ruetten, Mark Walker, Ewan Pearson, Paul W. Franks
Jun 15, 2020
Abstract: Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations...
Public trust and genomic medicine in Canada and the UK.
Background: Genomic medicine could improve precise risk stratification, early prevention, and personalised treatment across a broad spectrum of disease. As this reality approaches, questions on the importance of public trust...
Personalised prevention of type 2 diabetes.
Nicholas J Wareham
Sep 29, 2022
It is well established from clinical trials that behavioural interventions can halve the risk of progression from prediabetes to type 2 diabetes but translating this evidence of efficacy into effective real-world interventions...
Biomarker-guided trials
M Antoniou, R Kolamunnage-Dona, J Wason, R Bathia, C Billingham, JM Bliss, LC Brown, A Gillman, J Paul, AL Jorgensen
Dec 09, 2019
Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been...
Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients.
Jakub Tomasik, Emanuel Schwarz, Santiago G Lago, Matthias Rothermundt, F Markus Leweke, Nico JM van Beveren, Paul C Guest, Hassan Rahmoune, Johann Steiner, Sabine Bahn
Dec 04, 2015
biomarker CD36 FABP3 Olanzapine Personalised medicine Schizophrenia Adult Antipsychotic Agents Benzodiazepines CD36 Antigens Cohort Studies Fatty Acid Binding Protein 3 Fatty Acid-Binding Proteins Female Humans Interleukin-10 Male Middle Aged Olanzapine Quetiapine Fumarate Risperidone Schizophrenia Young Adult
Bayesian modelling strategies for borrowing of information in randomised basket trials.
Basket trials are an innovative precision medicine clinical trial design evaluating a single targeted therapy across multiple diseases that share a common characteristic. To date, most basket trials have been conducted in...
Response heterogeneity
Response rates to available treatments for psychological and chronic pain disorders are poor, and there is a considerable burden of suffering and disability for patients, who often cycle through several rounds of ineffective...
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes
Robert W Koivula, Ian M Forgie, Azra Kurbasic, Ana Viñuela, Alison Heggie, Giuseppe N Giordano, Tue H Hansen, Michelle Hudson, Anitra DM Koopman, Femke Rutters, Maritta Siloaho, Kristine H Allin, Søren Brage, Caroline A Brorsson, Adem Y Dawed, Federico De Masi, Christopher J Groves, Tarja Kokkola, Anubha Mahajan, Mandy H Perry, Simone P Rauh, Martin Ridderstråle, Harriet JA Teare, E Louise Thomas, Andrea Tura, Henrik Vestergaard, Tom White, Jerzy Adamski, Jimmy D Bell, Joline W Beulens, Søren Brunak, Emmanouil T Dermitzakis, Philippe Froguel, Gary Frost, Ramneek Gupta, Torben Hansen, Andrew Hattersley, Bernd Jablonka, Jane Kaye, Markku Laakso, Timothy J McDonald, Oluf Pedersen, Jochen M Schwenk, Imre Pavo, Andrea Mari, Mark I McCarthy, Hartmut Ruetten, Mark Walker, Ewan Pearson, Paul W Franks, IMI DIRECT Consortium
Apr 26, 2019
AIMS/HYPOTHESIS: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and...
Diet ectopic fat Genome glycaemic control Insulin Secretion insulin sensitivity Personalised medicine physical activity Prediabetes Type 2 diabetes Aged Biomarkers Blood Glucose Cohort Studies Diabetes mellitus Type 2 Female Glucose Glucose Tolerance Test Humans Male Metformin Middle Aged Prediabetic State Prospective Studies
Integration of copy number and transcriptomics provides risk stratification in prostate cancer
H Ross-Adams, AD Lamb, MJ Dunning, S Halim, J Lindberg, CM Massie, LA Egevad, R Russell, A Ramos-Montoya, SL Vowler, NL Sharma, J Kay, H Whitaker, J Clark, R Hurst, VJ Gnanapragasam, NC Shah, AY Warren, CS Cooper, AG Lynch, R Stark, IG Mills, H Grönberg, DE Neal, CamCaP Study Group
Jul 21, 2015
Biochemical relapse Gene signature Genomics Personalised medicine Prognosis prostate cancer Risk stratification Adult Aged Aged 80 and over Cluster Analysis Cohort Studies Gene Dosage Gene Expression Profiling Gene Expression Regulation Neoplastic Genome Human Humans Male Middle Aged Prognosis Prostatic Neoplasms RNA Messenger Recurrence Reproducibility of Results Risk Factors Transcriptome
Bayesian modelling strategies for borrowing of information in randomised basket trials.
Basket trials are an innovative precision medicine clinical trial design evaluating a single targeted therapy across multiple diseases that share a common characteristic. To date, most basket trials have been conducted in...